iRadimed Corporation (NASDAQ:IRMD) Receives $120.00 Consensus Target Price from Analysts

iRadimed Corporation (NASDAQ:IRMD) has received an average recommendation of “Buy” from the five ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $120.00.

A number of equities analysts have recently commented on IRMD shares. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Weiss Ratings cut shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th.

Insider Activity at iRadimed

In other news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $93.36, for a total value of $466,800.00. Following the completion of the sale, the chief executive officer owned 2,205,000 shares of the company’s stock, valued at $205,858,800. This represents a 0.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 32,500 shares of company stock worth $2,864,903 in the last 90 days. Insiders own 34.60% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quarry LP purchased a new stake in shares of iRadimed during the third quarter valued at approximately $40,000. Farther Finance Advisors LLC boosted its stake in shares of iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 397 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 495 shares during the period. CWM LLC grew its holdings in iRadimed by 19.5% during the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after purchasing an additional 107 shares in the last quarter. Finally, USA Financial Formulas purchased a new stake in iRadimed during the 4th quarter worth $82,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Stock Performance

iRadimed stock opened at $97.03 on Thursday. iRadimed has a one year low of $55.11 and a one year high of $107.90. The stock has a market cap of $1.24 billion, a PE ratio of 53.02 and a beta of 0.90. The stock has a 50-day moving average of $93.23 and a two-hundred day moving average of $95.94.

iRadimed (NASDAQ:IRMD) last posted its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.03. The firm had revenue of $21.98 million during the quarter, compared to the consensus estimate of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. As a group, sell-side analysts predict that iRadimed will post 1.52 EPS for the current fiscal year.

iRadimed Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Friday, May 15th were given a $0.20 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.8%. iRadimed’s dividend payout ratio (DPR) is 43.72%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.